...
首页> 外文期刊>Critical care medicine >Statins and outcomes in patients with bloodstream infection: A propensity-matched analysis
【24h】

Statins and outcomes in patients with bloodstream infection: A propensity-matched analysis

机译:他汀类药物和血流感染患者的预后:倾向匹配分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: The pleiotropic effects of statins, 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor, have been shown to modify inflammatory cell signaling on the immune response to infection. It was postulated that statins may be a good candidate as novel therapeutic agents for the treatment of sepsis. We investigated whether ongoing statin therapy is associated with mortality in patients with bloodstream infection. Design: A retrospective cohort study. Setting: Two tertiary hospitals in Bronx, NY. PATIENTS:: Adult patients in the hospital with bloodstream infection and categorized according to statin therapy as an outpatient or inpatient before bacteremia. Interventions: None. MEASUREMENT AND MAIN RESULTS:: Of 2,139 bacteremic hospitalized patients, 592 (28%) received statins before blood cultures and 677 (32%) died within 90 days. On multivariate adjustment, the association between statin therapy and 90-day all-cause mortality was statistically significant (hazard ratio, 0.78; 95% confidence interval [CI] 0.65-0.94), but statin users and nonusers differed significantly on many baseline clinical factors. Using the propensity score matched analysis to balance the differences between groups, the association was no longer significant (hazard ratio 0.99; 95% CI 0.77-1.25). Multivariate analysis after stratifying by decile in propensity score for statin use demonstrated similar results (hazard ratio 0.86; 95% CI 0.70-1.06). Statin use was not associated with reduced intensive care unit admission (odds ratio [OR], 0.86; 95% CI 0.59-1.26), hospital length of stay (β =-0.8 days; 95% CI-2.2 to 1.7 days), intensive care unit length of stay (β =-0.1 days; 95% CI-3.7 to 3.8 days), or need for mechanical or noninvasive ventilation (OR 1.03; 95% CI 0.70-1.51). Conclusion: After adjusting for the propensity to receive statin therapy, no statistically significant association between statin therapy before bloodstream infection and survival was identified.
机译:目的:他汀类药物3-羟基-3甲基戊二酰辅酶A还原酶抑制剂的多效性已被证明可以改变炎症细胞信号转导对感染的免疫反应。据推测,他汀类药物可能是败血症治疗的新型治疗剂。我们调查了正在进行的他汀类药物治疗是否与血液感染患者的死亡率相关。设计:一项回顾性队列研究。地点:纽约州布朗克斯市的两家三级医院。患者:医院中有血液感染的成年患者,根据他汀类药物治疗被分类为门诊或菌血症之前的住院患者。干预措施:无。测量和主要结果:在2139名经细菌治疗住院的患者中,有592名(28%)在血液培养前接受他汀类药物治疗,而677名(32%)在90天内死亡。在多变量调整中,他汀类药物治疗与90天全因死亡率之间的相关性具有统计学意义(危险比,0.78; 95%置信区间[CI] 0.65-0.94),但是他汀类药物使用者和非使用者在许多基线临床因素上存在显着差异。使用倾向得分匹配分析来平衡组之间的差异,该关联不再显着(危险比0.99; 95%CI 0.77-1.25)。使用他汀类药物的倾向得分按十分位数进行分层后的多变量分析显示了相似的结果(危险比0.86; 95%CI 0.70-1.06)。他汀类药物的使用与重症监护病房住院率的降低(赔率[OR],0.86; 95%CI 0.59-1.26),住院时间(β= -0.8天; 95%CI-2.2至1.7天),重症无关护理单位的住院时间(β= -0.1天; 95%CI-3.7至3.8天),或需要机械或无创通气(OR 1.03; 95%CI 0.70-1.51)。结论:在调整接受他汀类药物治疗的倾向后,未发现血液感染前他汀类药物治疗与生存之间的统计学显着相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号